respiratori
virus
rv
repres
one
lead
caus
communityacquir
pneumonia
file
de
roux
et
al
frequent
trigger
exacerb
asthma
chronic
obstruct
pulmonari
diseas
howev
contribut
acut
respiratori
failur
requir
intens
care
unit
admiss
extens
studi
lack
rapid
sensit
diagnost
method
absenc
effect
antivir
treatment
limit
interest
rv
detect
routin
recent
new
multiplex
molecular
assay
allow
detect
pathogen
hour
introduc
liolio
et
al
van
elden
et
al
reijan
et
al
could
impact
patient
care
particular
prescript
antiinfect
treatment
woo
et
al
barenfang
et
al
aim
studi
assess
burden
viral
infect
non
immunocompromis
patient
admit
intens
care
unit
acut
respiratori
failur
use
multiplex
molecular
assay
studi
also
aim
describ
clinic
characterist
viral
infect
bacteri
coinfect
seventi
non
immunocompromis
patient
admit
acut
respiratori
failur
close
intens
care
unit
teach
hospit
januari
juli
multiplex
molecular
assay
perform
respiratori
specimen
includ
present
studi
decis
perform
virolog
screen
discret
attend
physician
institut
review
board
clermont
ferrand
teach
hospit
approv
retrospect
observ
studi
waiv
need
inform
consent
acut
respiratori
failur
defin
respiratori
rate
greater
breath
per
minut
respiratori
distress
symptom
pao
room
air
lower
mmhg
need
ventilatori
support
patient
underw
noninvas
test
look
infect
includ
noninduc
sputum
examin
bacteria
mycobacteria
fungi
blood
cultur
urin
test
bacteri
antigen
whenev
possibl
patient
receiv
antibiot
sampl
bacteri
cultur
bronchoscopi
bronchoalveolar
lavag
perform
deem
appropri
attend
physician
bronchoalveolar
lavag
fluid
collect
describ
previous
azoulay
et
al
use
bacteri
mycobacteri
fungal
cultur
detect
rv
antigen
immunofluoresc
cytolog
examin
echocardiographi
chest
comput
tomographi
thoracocentesi
also
perform
deem
appropri
attend
physician
argen
verniol
franc
perform
routin
test
nasopharyng
aspir
bronchoalveolar
lavag
fluid
influenza
b
virus
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
adenovirus
human
metapneumoviru
hmpv
sought
start
octob
specimen
store
frozen
minu
process
multiplex
molecular
assay
end
inclus
period
total
nucleic
acid
purifi
ml
respiratori
specimen
use
easymag
system
marci
letoil
franc
elut
final
volum
ml
molecular
investig
rv
carri
use
multiplex
molecular
assay
pathofind
maastricht
netherland
detect
differenti
rv
includ
influenza
virus
b
rsv
b
rhinoviru
human
coronavirus
hmpv
adenoviru
addit
multiplex
molecular
assay
detect
influenza
four
bacteria
chlamydophila
pneumonia
mycoplasma
pneumonia
legionella
pneumophila
bordetella
pertussi
quantit
paramet
report
median
interquartil
rang
iqr
percentil
compar
use
mannwhitney
u
test
wilcoxon
test
appropri
qualit
paramet
report
number
percentag
compar
use
x
test
fisher
exact
test
appropri
odd
ratio
confid
interv
ci
comput
p
valu
less
consid
signific
statist
analys
perform
use
statview
sa
institut
cari
nc
seventi
patient
male
femal
median
age
iqr
year
includ
fourtyseven
mechan
ventil
circulatori
insuffici
need
renal
replac
therapi
median
simplifi
acut
physiolog
score
ii
median
intens
care
unit
length
stay
day
patient
die
hospit
main
diagnosi
admiss
acut
exacerb
chronic
obstruct
pulmonari
diseas
asthma
patient
commun
acquir
pneumonia
patient
noninfecti
lung
disesas
patient
fig
studi
patient
investig
rv
result
depict
tabl
nine
patient
rv
detect
stain
compar
patient
use
multiplex
molecular
assay
p
one
third
molecular
assay
posit
patient
infect
influenza
viru
two
patient
two
virus
detect
rhinoviru
one
rhinoviru
influenza
b
note
atyp
bacteria
detect
multiplex
molecular
assay
bacteri
examin
respiratori
specimen
perform
patient
posit
streptococcu
pneumonia
first
isol
bacteria
n
posit
molecular
assay
uniqu
posit
result
among
microbi
investig
patient
includ
patient
acut
exacerb
asthma
chronic
obstruct
pulmonari
diseas
stain
posit
patient
five
patient
isol
bacteri
infect
bacteri
viral
coinfect
tabl
ii
compar
patient
neg
molecular
assay
posit
molecular
assay
patient
without
bacteri
coinfect
often
treat
inhal
corticosteroid
vs
p
ci
often
bronchospasm
physic
examin
vs
p
ci
less
interstiti
infiltr
chest
radiographi
vs
p
ci
lower
hospit
mortal
vs
p
ci
patient
acut
exacerb
asthma
chronic
obstruct
pulmonari
diseas
prone
posit
multiplex
molecular
assay
compar
patient
commun
acquir
pneumonia
noninfecti
lung
diseas
vs
p
ci
subgroup
differ
baselin
characterist
symptom
outcom
found
posit
neg
molecular
assay
patient
studi
rv
detect
multiplex
molecular
assay
half
patient
admit
intens
care
unit
acut
respiratori
failur
pathogen
detect
rv
infect
patient
multiplex
molecular
assay
higher
sensit
stain
accordingli
previou
studi
liolio
et
al
van
elden
et
al
legoff
et
al
reijan
et
al
seemingli
higher
preval
rv
compar
previou
report
carrat
et
al
daubin
et
al
may
due
part
high
sensit
multiplex
molecular
assay
also
specif
characterist
studi
popul
cohort
patient
acut
exacerb
asthma
chronic
obstruct
pulmonari
diseas
prone
viral
infect
compar
patient
respiratori
virus
microbi
document
case
believ
clearli
emphas
major
role
rv
trigger
exacerb
patient
chronic
underli
respiratori
condit
couch
et
al
lieberman
et
al
sethi
howev
present
result
allow
firm
conclus
regard
exact
signific
rv
detect
molecular
screen
acut
respiratori
failur
detect
rv
molecular
assay
alon
associ
lower
viru
titer
fewer
report
respiratori
symptom
compar
result
univari
analysi
respiratori
virus
isol
patient
chronic
obstruct
respiratori
diseas
influenza
b
rsv
hmpv
adenoviru
rhinoviru
coronaviru
coronaviru
coronaviru
one
patient
viral
dual
infect
influenza
b
rhinoviru
respiratori
virus
isol
patient
communityacquir
pneumonia
influenza
rsv
piv
rhinoviru
coronaviru
one
patient
dual
viral
infect
rhinoviru
respiratori
virus
isol
patient
noninfecti
lung
diseas
influenza
adenoviru
rhinoviru
coronaviru
concomit
detect
molecular
assay
convent
method
jansen
et
al
suggest
molecular
method
may
allow
detect
mildli
symptomat
stage
rv
infect
even
asymptomat
viral
shed
thu
exclud
patient
exhibit
asymptomat
viral
shed
concomit
respiratori
failur
etiolog
final
one
third
studi
patient
infect
influenza
virus
miss
assay
first
underlin
role
influenza
sever
exacerb
chronic
obstruct
pulmonari
diseas
asthma
thu
critic
import
promot
vaccin
popul
second
result
support
need
rapid
influenza
diagnosi
ensur
proper
infect
control
measur
studi
report
lower
mortal
rate
patient
posit
multiplex
molecular
assay
compar
neg
assay
appar
better
prognosi
virusassoci
respiratori
disord
describ
studi
daubin
et
al
like
reflect
better
prognosi
acut
exacerb
chronic
respiratori
condit
compar
etiolog
acut
respiratori
failur
rapid
detect
isol
viral
infect
could
consid
shorten
even
withhold
antibiot
therapi
patient
exacerb
chronic
obstruct
pulmonari
diseas
asthma
patient
posit
molecular
assay
may
give
plausibl
etiolog
acut
respiratori
failur
event
thu
allow
stop
antibiot
patient
neg
bacteri
investig
even
withhold
antibiot
clinic
radiolog
sign
pneumonia
short
delay
hour
render
result
multiplex
molecular
assay
could
help
clinician
move
toward
object
howev
intensivist
may
reluct
stop
antibiot
set
acut
respiratori
failur
impact
molecular
test
rv
antibiot
consumpt
deserv
investig
final
atyp
bacteria
detect
despit
sizepopul
limit
also
taken
consider
probabilist
antibiot
treatment
monocent
retrospect
design
low
sampl
size
decis
perform
virolog
screen
let
discret
attend
physician
import
limit
hamper
interpret
clinic
impact
rv
detect
studi
particular
select
process
studi
patient
may
introduc
major
bia
one
hand
attend
physician
may
prone
perform
virolog
assay
patient
higher
probabl
rv
infect
ie
contact
infect
peopl
flulik
syndrom
hand
may
exclud
patient
welldefin
etiolog
acut
respiratori
failur
thu
miss
potenti
concomit
rv
infect
net
effect
observ
rv
infect
frequenc
remain
difficult
determin
hamper
interpret
present
result
studi
demonstr
high
diagnost
yield
viru
detect
use
singl
multiplex
molecular
assay
patient
admit
intens
care
unit
acut
respiratori
failur
especi
acut
exacerb
obstruct
respiratori
diseas
diagnost
tool
provid
result
hour
allow
reconsid
rv
detect
part
etiolog
investig
patient
acut
respiratori
failur
especi
acut
exacerb
asthma
chronic
obstruct
pulmonari
diseas
whether
rapid
diagnosi
translat
clinic
benefit
reduc
antibiot
appropri
costeffect
care
deserv
investig
